Skip to main content
    I

    Icecure Medical (ICCM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.76
    +0.03 (+4.12%)

    Market Cap: $3.39M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Icecure Medical (ICCM) Financials: Revenue, Profit and Cash Flow

    Updated Aug 12, 2026. Financial statements from company filings, amounts in US dollars.

    Icecure Medical reported revenue of $3.38M for the fiscal year ended Dec 31, 2025, up 2.7% from the year before. That year, net income was -$15.06M with a net margin of -445.6%, operating cash flow was -$14.57M and free cash flow was -$14.61M. The quarter ended Jun 30, 2026 had revenue of $907.00K and net income of -$4.50M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $625.49K, a compound annual rate of 20.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.38M+2.7%36.3%-446.7%-445.6%
    Dec 2024$3.29M+1.9%44.1%-476.9%-465.5%
    Dec 2023$3.23M+4.7%40.3%-482.4%-453.8%
    Dec 2022$3.08M-25.4%46.8%-542.6%-550.3%
    Dec 2021$4.14M+7.0%53.0%-235.0%-239.1%
    Dec 2020$3.87M+133.3%63.2%-107.1%-96.4%
    Dec 2019$1.66M+54.6%34.8%N/AN/A
    Dec 2018$1.07M+55.5%41.9%N/AN/A
    Dec 2017$689.38K+10.2%25.4%N/AN/A
    Dec 2016$625.49KN/A35.4%N/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.38M$3.29M$3.23M$3.08M$4.14M$3.87M$1.66M$1.07M$689.38K$625.49K
    Cost of revenue$2.15M$1.84M$1.93M$1.64M$1.94M$1.42M$1.08M$623.17K$514.44K$403.99K
    Gross profit$1.23M$1.45M$1.30M$1.45M$2.19M$2.44M$576.41K$448.73K$174.93K$221.49K
    Research and development$7.43M$7.10M$8.27M$9.12M$5.88M$3.81M$2.85M$1.94M$1.50M$1.66M
    Operating income-$15.09M-$15.70M-$15.58M-$16.74M-$9.72M-$4.14MN/AN/AN/AN/A
    Net income-$15.06M-$15.32M-$14.65M-$16.98M-$9.89M-$3.73MN/AN/AN/AN/A
    EBITDA-$14.80M-$15.36M-$15.25M-$16.25M-$9.43M-$4.08MN/AN/AN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$907.00K$911.00K$1.28M$850.00K$525.00K$725.00K$875.00K$662.00K$1.01M$743.00K$1.25M$327.00K
    Gross profit$253.00K$295.00K$600.00K$277.00K$131.00K$218.00K$417.00K$235.00K$530.00K$269.00K$569.00K-$23.00K
    Operating income$4.42M-$4.25M-$4.22M-$17.92M-$3.38M-$3.66M-$4.53M-$4.29M-$3.23M-$3.65M-$3.42M-$4.12M
    Net income-$4.50M-$4.27M-$4.25M-$3.86M-$3.36M-$3.59M-$4.48M-$4.15M-$3.08M-$3.61M-$3.00M-$4.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $204.00K by $8.69M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$13.89M$12.58M$16.41M$30.19M$32.28M$10.24M$7.32M$5.25M$1.93M$3.31M
    Current assets$12.61M$10.75M$14.18M$28.13M$30.32M$9.59M$6.90M$5.15M$1.86M$3.23M
    Cash and equivalents$8.90M$7.56M$10.53M$23.66M$25.62M$3.50M$5.78M$4.19M$1.46M$2.82M
    Total liabilities$4.84M$5.67M$4.25M$4.77M$5.32M$4.59M$4.69M$1.89M$2.19M$1.21M
    Short-term debt$204.00K$298.00K$223.00K$167.00K$224.00K$214.00K$134.57KN/A$936.24KN/A
    Shareholder equity$9.05M$6.90M$12.16M$25.42M$26.96M$5.65M$2.63M$3.37MN/A$2.10M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$17.71M$13.30M$13.89M$15.08M$10.59M$11.10M$12.58M$15.28M$15.36M$16.05M$16.41M$19.42M
    Total liabilities$5.81M$4.81M$4.84M$5.77M$7.70M$5.10M$5.67M$5.22M$4.75M$4.42M$4.25M$4.63M
    Cash and equivalents$12.03M$8.12M$8.90M$4.97M$5.38M$6.04M$7.56M$10.67M$9.65M$10.97M$10.53M$3.83M
    Shareholder equity$11.90M$8.49M$9.05M$9.31M$2.89M$6.00M$6.90M$10.06M$10.61M$11.64M$12.16M$14.79M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$14.57M-$12.56M-$12.52M-$14.29M-$12.61M-$3.69MN/AN/AN/AN/A
    Capital expenditures$36.00K$71.00K$480.00K$891.00K$533.00K$223.00KN/AN/AN/AN/A
    Free cash flow-$14.61M-$12.63M-$13.00M-$15.18M-$13.14M-$3.91MN/AN/AN/AN/A
    Investing cash flow-$36.00K$446.00K-$713.00K-$891.00K$3.79M-$4.67MN/AN/AN/AN/A
    Financing cash flow$15.83M$9.19M$83.00K$13.58M$30.89M$5.86M$3.06M$5.98M$1.05M$1.40M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$3.88M-$4.27M-$5.47M-$2.71M-$2.81M-$4.04M-$4.20M-$3.15M-$2.36M-$2.85M-$2.64M-$3.32M
    Capital expenditures$10.00K$51.00K$5.77K$3.00K$22.00K$6.00K$5.00K$32.00K$6.00K$28.00K$81.00K$77.00K
    Free cash flow-$3.89M-$4.32M-$5.47M-$2.71M-$2.83M-$4.04M-$4.20M-$3.19M-$2.37M-$2.88M-$2.73M-$3.39M
    Last 12 quarters

    Frequently Asked Questions About ICCM

    What is Icecure Medical's annual revenue?

    Icecure Medical reported revenue of $3.38M for the fiscal year ended Dec 31, 2025.

    How fast is Icecure Medical's revenue growing?

    Revenue was up 2.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.1%.

    Is Icecure Medical profitable?

    No. Icecure Medical reported net income of -$15.06M for the fiscal year ended Dec 31, 2025, with a net margin of -445.6%.

    How much free cash flow does ICCM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$14.57M minus capital expenditures of $36.00K produced free cash flow of -$14.61M.

    How much debt does Icecure Medical have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $204.00K and cash and equivalents of $8.90M.